Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT06619600
PHASE3

Effect of Dapagliflozin in Myocardial Fibrosis and Ventricular Function in Patients With a ST-segment Elevation Myocardial Infarction

Sponsor: Hospital Clinic of Barcelona

View on ClinicalTrials.gov

Summary

The DAPA-STEMI trial investigates whether dapagliflozin, a sodium-glucose cotransporter 2 inhibitor (SGLT2i), reduces heart muscle scarring (fibrosis) and improves heart function after a ST-segment elevation myocardial infarction (STEMI). The trial will use cardiac MRI to measure changes in heart structure and function over six months. Patients aged 30-85 who have had a recent STEMI will receive either dapagliflozin or a placebo. The study aims to provide mechanistic insights into heart failure prevention after heart attacks.

Key Details

Gender

All

Age Range

30 Years - 85 Years

Study Type

INTERVENTIONAL

Enrollment

54

Start Date

2021-05-30

Completion Date

2025-03-31

Last Updated

2025-02-19

Healthy Volunteers

No

Interventions

DRUG

Dapagliflozin

Dapagliflozin 10 mg qd

DRUG

Placebo

Matched placebo qd

Locations (2)

Hospital de la Santa Creu i Sant Pau

Barcelona, Catalonia, Spain

Hospital Clinic of Barcelona

Barcelona, Catalonia, Spain